In this section
MACC Fund Center for Cancer and Blood Disorders
- Programs and services
- Clinical trials
- Participate in a clinical trial
- For medical professionals
- Active clinical trials for pediatric cancers
- Alpha Beta T-cell and B-cell depleted allogeneic transplantation followed by Blinatumomab therapy for high-risk B-Acute Lymphoblastic Leukemia pilot study
- Blinatumomab bridging therapy in high-risk B-ALL clinical trial
- CAR-20/19-T cells in pediatric and young adult patients with relapsed/refractory B Cell Acute Lymphoblastic Leukemia (CAR-20/19-T) phase 1 clinical trial
- Unrelated and partially matched related donor peripheral stem cell transplantation for patients with hematologic malignancies clinical trial
- Early stage research
- Patient stories
- Our specialists
- For medical professionals
- Contact us
- Diet and nutritional care
- Our philanthropic partners
- Get a second opinion
- Patient family information
Blinatumomab bridging therapy in high-risk B-Acute Lymphoblastic Leukemia - phase 2 study
Children’s Wisconsin is currently enrolling patients up to 25 years old on a phase 2 study using blinatumomab as a bridging therapy to stem cell transplant. Dr Michael Burke is the Primary Investigator and Study Chair. This study will be testing the ability of a biologically active therapy in blinatumomab, an anti-CD19/CD3 bispecific T-cell engager, to further reduce residual leukemia immediately prior to stem cell transplant to improve post-transplant outcomes. We anticipate enrolling 35 participants in the next 3 years.
This study will determine the effectiveness of delivering 1 to 2 cycles of blinatumomab (Days 1-28) as bridging therapy in children, adolescent and young adults with relapse or persistent minimal residual disease (MRD) B-ALL. Eligible patients will receive 1 or 2, 28-day cycles of blinatumomab prior to proceeding to hematopoietic stem cell transplantation (HCT). Centralized MRD assessment will be performed after completion of the 28-days of blinatumomab using both flow cytometry (University of Washington, Brent Wood, MD) and High-Throughput Deep Sequencing (HTS) MRD technologies (Adaptive Technologies, Seattle, WA). Subjects who achieve flow cytometry negative MRD (<0.01%) after a single cycle of blinatumomab can proceed directly to HCT whereas subjects who remain MRD positive by flow cytometry may receive a 2nd cycle of blinatumomab. Subjects who remain MRD positive by flow cytometry after a 2nd cycle of blinatumomab will come off study.
ClinicalTrials.gov identifier (NCT number): NCT04556084
For more information contact: Amberley Kemic | Clinical Research RN | 414-266-2038
For more information about cancer and blood disorders clinical trials, email us or call
Get a second opinion
It's important to know what your options are. We can provide expert opinions to verify or give more information about an initial diagnosis. Contact us today.
Why participate in clinical trials?
"The steady improvement in survival for children with cancer is a direct result of their enrollment onto clinical trials; without which we would remain decades behind in terms of scientific advances in pediatric cancer." ~Michael J. Burke, MD